Anixa Biosciences (ANIX) Competitors $2.56 -0.05 (-1.92%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.58 +0.02 (+0.98%) As of 05/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. HUMA, SNDL, CDTX, CYRX, OLMA, ARCT, ITOS, PHAT, ATYR, and TRDAShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Humacyte (HUMA), SNDL (SNDL), Cidara Therapeutics (CDTX), Cryoport (CYRX), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), iTeos Therapeutics (ITOS), Phathom Pharmaceuticals (PHAT), Atyr PHARMA (ATYR), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Humacyte SNDL Cidara Therapeutics Cryoport Olema Pharmaceuticals Arcturus Therapeutics iTeos Therapeutics Phathom Pharmaceuticals Atyr PHARMA Entrada Therapeutics Humacyte (NASDAQ:HUMA) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Does the media refer more to HUMA or ANIX? In the previous week, Humacyte had 12 more articles in the media than Anixa Biosciences. MarketBeat recorded 13 mentions for Humacyte and 1 mentions for Anixa Biosciences. Humacyte's average media sentiment score of 0.55 beat Anixa Biosciences' score of 0.00 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate HUMA or ANIX? Humacyte currently has a consensus price target of $11.71, suggesting a potential upside of 400.61%. Anixa Biosciences has a consensus price target of $9.00, suggesting a potential upside of 251.56%. Given Humacyte's higher possible upside, equities research analysts clearly believe Humacyte is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is HUMA or ANIX more profitable? Anixa Biosciences' return on equity of -58.55% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% Anixa Biosciences N/A -58.55%-53.29% Which has more volatility & risk, HUMA or ANIX? Humacyte has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Do institutionals & insiders believe in HUMA or ANIX? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 5.1% of Humacyte shares are held by company insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, HUMA or ANIX? Anixa Biosciences has lower revenue, but higher earnings than Humacyte. Anixa Biosciences is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$517K702.09-$110.78M-$0.69-3.39Anixa Biosciences$210K392.50-$12.55M-$0.39-6.56 Does the MarketBeat Community favor HUMA or ANIX? Humacyte received 11 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 76.19% of users gave Anixa Biosciences an outperform vote while only 71.67% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes4371.67% Underperform Votes1728.33% Anixa BiosciencesOutperform Votes3276.19% Underperform Votes1023.81% SummaryHumacyte beats Anixa Biosciences on 10 of the 17 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.42M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-6.568.9226.7719.71Price / Sales392.50253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book4.346.466.794.50Net Income-$12.55M$143.98M$3.23B$248.18M7 Day Performance1.59%2.03%1.53%0.20%1 Month Performance-5.88%4.11%10.06%12.37%1 Year Performance-1.54%-2.87%16.74%7.04% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences1.7167 of 5 stars$2.56-1.9%$9.00+251.6%-6.2%$82.42M$210,000.00-6.565Gap UpHUMAHumacyte2.3029 of 5 stars$2.23-0.4%$11.71+425.3%-66.7%$345.92M$1.57M-1.66150Analyst RevisionGap UpSNDLSNDL3.0665 of 5 stars$1.30-3.7%$3.63+178.8%-44.5%$341.61M$927.61M-4.19580Positive NewsCDTXCidara Therapeutics4.4689 of 5 stars$26.49+3.9%$41.71+57.5%+147.2%$332.37M$302,000.00-1.0490High Trading VolumeCYRXCryoport3.0008 of 5 stars$6.58-1.5%$11.00+67.2%-48.4%$329.90M$232.13M-1.951,020Positive NewsOLMAOlema Pharmaceuticals2.2652 of 5 stars$4.80+1.9%$24.50+410.4%-46.5%$328.13MN/A-2.1970ARCTArcturus Therapeutics2.9267 of 5 stars$11.99+2.9%$57.80+382.1%-59.3%$325.18M$131.27M-5.40180ITOSiTeos Therapeutics2.9745 of 5 stars$8.41+7.7%$17.86+112.3%-54.4%$321.88M$35M-2.6790Positive NewsAnalyst RevisionGap UpHigh Trading VolumePHATPhathom Pharmaceuticals3.8778 of 5 stars$4.39+7.3%$17.60+300.9%-63.7%$306.48M$81.86M-0.77110Positive NewsGap DownATYRAtyr PHARMA2.8106 of 5 stars$3.44+5.2%$18.60+440.7%N/A$306.17M$235,000.00-3.6653Analyst ForecastTRDAEntrada Therapeutics2.947 of 5 stars$8.01-1.0%$25.67+220.4%-51.0%$304.00M$172.22M5.04110News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Humacyte Alternatives SNDL Alternatives Cidara Therapeutics Alternatives Cryoport Alternatives Olema Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives iTeos Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Atyr PHARMA Alternatives Entrada Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANIX Stock Free ANIX Stock Alerts